ArticleAnnals of surgical oncology2025

ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma.

Yawen Dong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.